Allergan Makes $588M Acquisition Play Amid Valeant Fight
Struggling against a high-profile takeover campaign launched by Valeant Pharmaceuticals International Inc., Allergan Inc. late on Wednesday unveiled an acquisition of its own in a deal worth up to $587.5 million...To view the full article, register now.
Already a subscriber? Click here to view full article